Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Director · President and CEO | February 12, 2024 | February 14, 2024 |
| Indivior Pharmaceuticals, Inc.INDV · Entity 4040 | Director · Chief Executive Officer | June 22, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COLLEGIUM PHARMACEUTICAL, INC
Report date February 12, 2024 · Filed February 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 444,867 |
Ending reported balance
After 2024-02-12 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2024-02-12 · Grant · Acquired 119,000 · Balance 394,000 F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2025, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Row 2 · 2024-02-12 · Grant · Acquired 179,734 · Balance 573,734 F2: Effective February 12, 2024, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 179,734 performance share units ("PSUs") granted in the Issuer's three prior fiscal years. Row 3 · 2024-02-12 · Tax withholding · Disposed 47,445 · Balance 526,289 F3: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs. Row 4 · 2024-02-12 · Tax withholding · Disposed 81,422 · Balance 444,867 F4: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2025, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
F2: Effective February 12, 2024, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 179,734 performance share units ("PSUs") granted in the Issuer's three prior fiscal years.
F3: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs.
F4: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.
Indivior Pharmaceuticals, Inc.
Report date June 22, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 790,330 |
Ending reported balance
After 2026-06-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-22 · Exercise / conversion · Acquired 1,266,903 · Balance 1,402,879 F1: Represents the vesting of performance stock units upon the determination that the performance conditions were met at 100% with respect to the performance stock units granted to the Reporting Person on May 13, 2025. As a result, 1,266,903 shares vested on June 22, 2026. F2: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-06-22 · Tax withholding · Disposed 612,549 · Balance 790,330 F3: Shares withheld to satisfy tax withholding obligations associated with the vesting of performance stock units on June 22, 2026. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-22 · Exercise / conversion · Disposed 1,266,903 · Balance 0 F2: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock. F1: Represents the vesting of performance stock units upon the determination that the performance conditions were met at 100% with respect to the performance stock units granted to the Reporting Person on May 13, 2025. As a result, 1,266,903 shares vested on June 22, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the vesting of performance stock units upon the determination that the performance conditions were met at 100% with respect to the performance stock units granted to the Reporting Person on May 13, 2025. As a result, 1,266,903 shares vested on June 22, 2026.
F2: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: Shares withheld to satisfy tax withholding obligations associated with the vesting of performance stock units on June 22, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2019 Filed Jul 2, 2019 22:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 1,848 | $13.21 | $24,412.08 |
DisclosureSEC source: 0001192482-19-000308 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,374 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 20:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 7,436 | $11.59 | $86,183.24 |
DisclosureSEC source: 0001192482-19-000274 · edgar.xml · nonDerivative · entry 3 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,222 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2018. F4 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.45 to $11.72, inclusive Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 20:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 3,097 | $11.51 | $35,646.47 |
DisclosureSEC source: 0001192482-19-000274 · edgar.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,658 F3 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 20:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 5,851 | $11.52 | $67,403.52 |
DisclosureSEC source: 0001192482-19-000274 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,755 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2018. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.44 to $11.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4). Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 22:01 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 2,052 | $14.39 | $29,528.28 |
DisclosureSEC source: 0001192482-19-000073 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,606 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 21:33 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 90,000 | $0.00 Strike: $15.90 | $0.00 |
DisclosureSEC source: 0001192482-19-000053 · edgar.xml · derivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-01-25 F2 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2020, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 21:33 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000053 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,658 F1 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2020, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 22:05 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 4,683 | $19.19 | $89,866.77 |
DisclosureSEC source: 0001192482-18-000484 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,658 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| July 01, 2018 Filed Jul 2, 2018 21:44 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 41,418 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001192482-18-000329 · edgar.xml · derivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,418 Underlying: Common Stock · 41,418 shares Expires 2028-07-01 F2 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on July 1, 2019, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer. Read SEC document |
| July 01, 2018 Filed Jul 2, 2018 21:44 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 25,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-18-000329 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,341 F1 · shares: Reflects the grant of restricted stock units in connection with the reporting person's promotion to Chief Executive Officer of the issuer. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on July 1, 2019, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 22:00 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 14,862 | $22.48 | $334,097.76 |
DisclosureSEC source: 0001192482-18-000260 · edgar.xml · nonDerivative · entry 5 Ciaffoni Joseph · CIK 0001443841 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,201 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2017. F5 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.14 to $22.91, inclusive. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 22:00 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock option (right to purchase) · Derivative | 64,821 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001192482-18-000260 · edgar.xml · derivative · entry 6 Ciaffoni Joseph · CIK 0001443841 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,462 Underlying: Common Stock · 64,821 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 64,821 shares subject to the option vested and became exercisable on May 31, 2018. The remaining 194,462 shares subject to the option vest in equal quarterly installments (rounded up to the nearest whole share of common stock) over a three year period, subject to the reporting person's continued service with the issuer. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 22:00 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 6,205 | $22.62 | $140,357.10 |
DisclosureSEC source: 0001192482-18-000260 · edgar.xml · nonDerivative · entry 4 Ciaffoni Joseph · CIK 0001443841 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,063 F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 22:00 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 5,617 | $23.35 | $131,156.95 |
DisclosureSEC source: 0001192482-18-000260 · edgar.xml · nonDerivative · entry 3 Ciaffoni Joseph · CIK 0001443841 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,268 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2017. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.10 to $23.45, inclusive. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 22:00 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 59,204 | $22.54 | $1,334,458.16 |
DisclosureSEC source: 0001192482-18-000260 · edgar.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,885 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2017. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.10 to $23.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (5). Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 22:00 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 64,821 | $8.22 | $532,828.62 |
DisclosureSEC source: 0001192482-18-000260 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2018 Filed Jan 30, 2018 00:39 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 50,000 | $0.00 Strike: $24.35 | $0.00 |
DisclosureSEC source: 0001192482-18-000065 · edgar.xml · derivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-01-25 F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on February 10, 2018. Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2019, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the reporting person's continued service with the issuer. Read SEC document |
| January 25, 2018 Filed Jan 30, 2018 00:39 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-18-000065 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,268 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest over a four-year period commencing on February 10, 2018. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2019, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vest date in shares of the issuer's common stock. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 20:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 259,283 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001192482-17-000152 · edgar.xml · derivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,283 Underlying: Common Stock · 259,283 shares Expires 2027-05-31 F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on May 31, 2017. Twenty-five percent (25%) of the option vests and becomes exercisable on May 31, 2018, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the reporting person's continued service with the issuer. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 20:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 84,268 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-17-000152 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,268 F1 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest over a four-year period commencing on May 31, 2017. Twenty-five percent (25%) of the restricted stock units vest on May 31, 2018, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.